Cameron LaBar, now in his early 30s, reflects on a lifelong journey shaped by psychiatric medication, beginning when he was prescribed antidepressants at age nine. Diagnosed in elementary school with Tourette’s syndrome, obsessive-compulsive disorder (OCD), and generalized anxiety disorder, LaBar’s mother sought medical help after observing his repetitive tics and extreme anxiety. A pediatric neurologist recommended Paxil, a selective serotonin reuptake inhibitor (SSRI), to help ease his symptoms and improve his functioning in school.

LaBar’s story illustrates a broader challenge faced by millions of Americans: the widespread use of SSRIs and other psychiatric drugs, alongside the limited knowledge and guidance about how to safely discontinue their use. Since the release of Prozac in 1988, SSRIs have become a common treatment for mental health disorders due to their relative safety and tolerability. However, few patients and clinicians have received adequate information about withdrawal symptoms when tapering off these medications.

Over two decades, LaBar cycled through several psychiatric drugs to manage his conditions, including Risperdal, Seroquel, Abilify, Orap, and Clonidine, alongside various SSRIs. Side effects such as weight gain and drowsiness often led to medication changes. Despite these challenges, he remained on antidepressants throughout adolescence and adulthood. The explanation he received—that a chemical imbalance required consistent treatment—provided comfort but also fostered a reliance on medication without clear plans for eventual discontinuation.

In his late 20s, after moving to Boise, Idaho, LaBar experienced severe mood swings and a sense of emotional numbness he attributes to long-term drug use. Seeking a way out, he began tapering his medications based on emerging approaches like hyperbolic tapering, which reduces drug doses more gradually as they approach zero. This method, advocated by experts such as Dr. Mark Horowitz of Adelaide University in Australia, contrasts with typical clinical practices and can take months or years.

LaBar’s withdrawal from Klonopin, a benzodiazepine prescribed for anxiety, proved particularly difficult. Symptoms included insomnia, heart palpitations, and worsened depression. However, after cessation, he reported a renewed sense of clarity and stability. His subsequent attempts to reduce Lexapro, another SSRI, triggered severe emotional blunting and suicidal thoughts, leading him to pause his taper and seek support from his family and mental health professionals.

The complexity of antidepressant withdrawal is not widely recognized within mainstream psychiatry. The American Psychiatric Association acknowledges that while many patients discontinue medication without significant issues, a subset experience protracted withdrawal symptoms lasting weeks or months. Research into optimal tapering protocols and long-term outcomes remains scant, creating a knowledge gap that has led many patients to turn to online communities for support and guidance.

This dynamic has drawn the attention of public figures such as Robert F. Kennedy Jr., who, as U.S. health secretary, has emphasized the need to address overmedicalization in mental health care and promote safer deprescribing practices. Some medical experts caution against hastily stopping medications due to risks of relapse or worsening symptoms, advocating for individualized treatment plans and more research on deprescribing.

LaBar has emerged as a vocal advocate for greater awareness of withdrawal challenges, sharing his experience on social media under the slogan “Free the feelings.” While he does not endorse specific medical advice, he aims to illuminate the complexities patients face when attempting to regain autonomy over their mental health.

Currently, LaBar is engaged in a meticulous tapering process, reducing his Lexapro dose by tiny increments with medical supervision. His goal is to discontinue medication entirely over several years, recognizing the slow pace required to avoid severe withdrawal effects. Despite obstacles including a resurgence of OCD symptoms, LaBar remains committed to understanding and managing his condition without medication.

Mental health specialists emphasize that successful deprescribing will require expanded clinical resources, careful monitoring, and individualized patient care. Without such support, efforts to reduce medication reliance risk leaving patients without effective alternatives. LaBar’s experience underscores the need for a more nuanced approach to psychiatric treatment—one that balances medication benefits with the challenges of withdrawal and the pursuit of personal autonomy.